A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Trial Profile

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH2
  • Sponsors Novartis
  • Most Recent Events

    • 31 Mar 2017 According to an Incyte Corporation media release, the first patient entered in this trial.
    • 10 Mar 2017 Planned primary completion date changed from 22 Oct 2018 to 30 Sep 2020.
    • 14 Feb 2017 According to Incyte Corporation media release, this trial is expected to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top